Zejun Yan
YOU?
Author Swipe
View article: Prognostic significance of peripheral blood inflammatory biomarkers (SII, PLR, NLR, LMR, SIRI, PIV, PNI) in lip cancer: NLR as an independent biomarker for survival outcomes
Prognostic significance of peripheral blood inflammatory biomarkers (SII, PLR, NLR, LMR, SIRI, PIV, PNI) in lip cancer: NLR as an independent biomarker for survival outcomes Open
Background Lip cancer is a type of oral cancer with a different prognosis than that of other cancers. However, a lack of well-established understanding of the relationship between the peripheral blood inflammatory biomarker (PBIB) and prog…
View article: A Novel Modular Multi-Unit Cell Permanent Magnet Thrust Bearing with Bionic Design and Load-Carrying Capacity Analysis
A Novel Modular Multi-Unit Cell Permanent Magnet Thrust Bearing with Bionic Design and Load-Carrying Capacity Analysis Open
Permanent magnet thrust bearings have garnered significant attention due to their high rotational speeds, low noise levels, and excellent vibration-damping performance. However, existing designs of these bearings often suffer from low load…
View article: Progress in the application of hyperspectral imaging techniques to quality inspection of dry-cured ham
Progress in the application of hyperspectral imaging techniques to quality inspection of dry-cured ham Open
View article: The relationship between the Barthel Index and stroke-associated pneumonia in elderly patients and factors of SAP
The relationship between the Barthel Index and stroke-associated pneumonia in elderly patients and factors of SAP Open
View article: Does Social Trust Promote Corporate New Quality Productive Force?
Does Social Trust Promote Corporate New Quality Productive Force? Open
View article: P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA Open
Background: Ruxolitinib, a potent and selective inhibitor of Janus kinase 1 (JAK1)/JAK2 tyrosine kinases, was approved for treatment of intermediate- and high-risk patients with myelofibrosis (MF) based on the findings from the pivotal stu…